Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver A Kent

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Hepatobiliary Surgery and Nutrition|December 1, 2018
Increased mutant <i>KRAS</i> gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?Oliver A Kent
Oncotargets and Therapy|January 30, 2025
Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1Kévin Leguay, Oliver A Kent
Organic & Biomolecular Chemistry|July 16, 2004
RNAi: running interference for the cellOliver A Kent, Andrew M MacMillan
Nature Structural Biology|July 2, 2002
Early organization of pre-mRNA during spliceosome assemblyOliver A Kent, Andrew M MacMillan
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2008
Proteins specifically modified with a chemical nuclease as probes of RNA-protein interactionOliver A Kent, Andrew M Macmillan
Journal of Visualized Experiments : Jove|July 10, 2018
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-spongeOliver A Kent, Charles Steenbergen, Samarjit Das
Molecular Cancer Research : MCR|January 10, 2016
Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1Oliver A Kent, Joshua T Mendell, Robert Rottapel
Small Gtpases|June 29, 2017
Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibitionOliver A Kent, Maria-Jose Sandi, Robert Rottapel
Oncotargets and Therapy|November 17, 2022
Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian CarcinomaEva Colic, Preya U Patel, Oliver A Kent
Methods (San Diego, Calif.)|July 4, 2017
Radical probing of spliceosome assemblyCharnpal S Grewal, Oliver A Kent, Andrew M MacMillan
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Hepatobiliary Surgery and Nutrition|December 1, 2018
Increased mutant <i>KRAS</i> gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?Oliver A Kent
Oncotargets and Therapy|January 30, 2025
Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1Kévin Leguay, Oliver A Kent
Organic & Biomolecular Chemistry|July 16, 2004
RNAi: running interference for the cellOliver A Kent, Andrew M MacMillan
Nature Structural Biology|July 2, 2002
Early organization of pre-mRNA during spliceosome assemblyOliver A Kent, Andrew M MacMillan
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2008
Proteins specifically modified with a chemical nuclease as probes of RNA-protein interactionOliver A Kent, Andrew M Macmillan
Journal of Visualized Experiments : Jove|July 10, 2018
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-spongeOliver A Kent, Charles Steenbergen, Samarjit Das
Molecular Cancer Research : MCR|January 10, 2016
Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1Oliver A Kent, Joshua T Mendell, Robert Rottapel
Small Gtpases|June 29, 2017
Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibitionOliver A Kent, Maria-Jose Sandi, Robert Rottapel
Oncotargets and Therapy|November 17, 2022
Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian CarcinomaEva Colic, Preya U Patel, Oliver A Kent
Methods (San Diego, Calif.)|July 4, 2017
Radical probing of spliceosome assemblyCharnpal S Grewal, Oliver A Kent, Andrew M MacMillan
Pageof 4